Step by Step


ABIM MOC Activity ID

12/14/2021 - Medical Grand Rounds: Endocrinology: Year in Review





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  1. Describe the appropriate usage of GLP1-agonists in patients with diabetes or elevated BMI
  2. Explain the role of technology in type 2 diabetes management
  3. Improve ordering of hormonal laboratory workup to facilitate interpretation and decrease misdiagnosis
  4. Improve patient counseling on risks and benefits of gender affirming hormone therapy
  5. Review treatment options for Graves disease to allow for appropriate early referral to ophthalmology

Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements & Suggested Additional Reading:

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Suggested Additional Reading

  1. Wilding et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021 Mar 18; 384(11):989. PMID: 33567185
  2. Jaffe G et al. "Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study." Hypertension 2020 Mar; 75(3): 650-659.
  3. Douglas RJ et al. "Teprotumumab for the Treatment of Active Thyroid Eye Disease." NEJM 2020; 382: 341-52
  4. Shim SR. "Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism A Systematic Review and Meta-analysis." JAMA Netw Open 2021; 4(9):e2125072. PMID 34533571

Janet Leung, MD — Clinical Assistant Professor of Medicine, Division of Endocrinology and Metabolism, Associate Program Director, Quality Improvement for Endocrine Fellowship, Clinical Lead, Quality Improvement, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.